| P. Lynch/Univ. of Texas M.D. Anderson Cancer Center |
Prephenotypic FAP |
Celecoxib vs. placebo |
Open |
| F. Meyskens/Univ. of California-Irvine |
Prior sporadic adenoma |
Sulindac + eflornithine vs. placebo |
Open |
| P. Lynch/Univ. of Texas M.D. Anderson Cancer Center |
Phenotypic FAP |
Celecoxib + eflornithine vs. celecoxib |
Open |
| R. Bresalier/Univ. of Texas M.D. Anderson Cancer Center |
Individuals with ACF |
Sulindac vs. aspirin vs. ursodiol vs. placebo |
Closed |
